How reducing labor time can save on your cell therapy manufacturing costs

In the early clinical development stage of autologous cell therapy manufacture, labor costs often dominate the overall cost of goods sold. However, as manufacturing scales out, the cost of materials — including media and reagents, consumables, and viral vectors — increases as a percentage of the total COGS. Ultimately, economies of scale can be achieved with autologous cell therapy processing. But, in order to widen access to these life-saving treatments, it’s crucial that manufacturers utilize solutions that can support reductions in labor costs.

In this webinar, our speakers explain how you can reduce labor time for certain critical steps of autologous cell therapy manufacturing by using automated and closed systems. They’ll compare operator tasks in a standard process versus a process using Cytiva systems for specific steps — such as cell expansion, mononuclear cell enrichment, and cryopreservation.

- Identify the challenges faced in the industry today
- Understand the benefits of automated and closed systems
- Discover how Cytiva systems such as Xuri™ Cell Expansion System W25, Sepax™ C-Pro system, and VIA Freeze™ instruments can help to reduce labor time and save costs